Rock Springs Capital Management LP 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 10:45 am Sale | 2025-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 5,046,309 4.700% | -1,715,552 (-25.37%) | Filing |
| 2024-11-22 4:00 pm Purchase | 2024-11-18 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 6,761,861 6.320% | 3,763,366 (+125.51%) | Filing |
| 2024-02-14 2:06 pm Sale | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 2,998,495 4.230% | -962,754 (-24.30%) | Filing |
| 2023-02-14 2:49 pm Purchase | 2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 3,961,249 5.940% | 99,902 (+2.59%) | Filing |
| 2022-02-14 6:22 pm Purchase | 2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 3,861,347 6.310% | 1,185,247 (+44.29%) | Filing |
| 2021-02-16 4:32 pm Purchase | 2020-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Rock Springs Capital Management LP | 2,676,100 6.240% | 462,244 (+20.88%) | Filing |